NEC Corporation (NIPNF)
| Previous close | 68.91 |
| Open | 68.91 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 68.91 - 68.91 |
| 52-week range | 37.71 - 77.01 |
| Volume | |
| Avg. volume | 62 |
| Market cap | 18.936B |
| Beta (5Y monthly) | 0.35 |
| PE ratio (TTM) | 23.44 |
| EPS (TTM) | 2.94 |
| Earnings date | N/A |
| Forward dividend & yield | 0.79 (1.15%) |
| Ex-dividend date | 28 Mar 2024 |
| 1y target est | N/A |
GuruFocus.comNEC Corp's Dividend Analysis
NEC Corp (NIPNF) recently announced a dividend of $0.60 per share, payable on a date yet to be announced, with the ex-dividend date set for 2024-03-28. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates. Using the data from GuruFocus, let's look into NEC Corp's dividend performance and assess its sustainability.
PR NewswireNEC and Sumitomo Corporation Sign Strategic Partnership Agreement to Expand Global Sales of the CropScope Agricultural ICT Platform
NEC Corporation (NEC; TSE: 6701) and Sumitomo Corporation (Sumitomo) have signed a strategic partnership agreement to expand global sales of NEC's agricultural ICT platform CropScope. Based on this partnership, NEC and Sumitomo aim to develop markets mainly in South America and the ASEAN region by utilizing Sumitomo's global network. To this end, NEC will expand the range of crops from the tomato farming support it has been focusing on and add functions to optimize and streamline a series of pro
Business WireTransgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
STRASBOURG, France & TOKYO & WALTHAM, Mass., March 05, 2024--Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, NEC Corporation (NEC; TSE: 6701), a leader in IT, network and AI technologies and BostonGene Corporation (BostonGene), a leading company in AI-based molecular and immune profiling, today announced the expansion of their collaboration for the randomized Phase I/II trial of TG4050, an individualized therap
